Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ramón Cacabelos. (2022) What have we learnt from past failures in Alzheimer’s disease drug discovery?. Expert Opinion on Drug Discovery 17:4, pages 309-323.
Read now
Read now
Ramón Cacabelos, Iván Carrera, Olaia Martínez-Iglesias, Natalia Cacabelos & Vinogran Naidoo. (2021) What is the gold standard model for Alzheimer’s disease drug discovery and development?. Expert Opinion on Drug Discovery 16:12, pages 1415-1440.
Read now
Read now
Marjan Talebi, Eleni Kakouri, Mohsen Talebi, Petros A. Tarantilis, Tahereh Farkhondeh, Selen İlgün, Ali Mohammad Pourbagher-Shahri & Saeed Samarghandian. (2021) Nutraceuticals-based therapeutic approach: recent advances to combat pathogenesis of Alzheimer’s disease. Expert Review of Neurotherapeutics 21:6, pages 625-642.
Read now
Read now
Ramón Cacabelos. (2020) Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:8, pages 673-701.
Read now
Read now
Ramon Cacabelos. (2020) Pharmacogenomics of drugs used to treat brain disorders. Expert Review of Precision Medicine and Drug Development 5:3, pages 181-234.
Read now
Read now
Ramón Cacabelos. (2020) How plausible is an Alzheimer’s disease vaccine?. Expert Opinion on Drug Discovery 15:1, pages 1-6.
Read now
Read now
Ramón Cacabelos. (2018) Population-level pharmacogenomics for precision drug development in dementia. Expert Review of Precision Medicine and Drug Development 3:3, pages 163-188.
Read now
Read now
Articles from other publishers (36)
Ramón Cacabelos, Juan C Carril, Lola Corzo, Rocío Pego, Natalia Cacabelos, Margarita Alcaraz, Adriana Muñiz, Olaia Martínez-Iglesias & Vinogran Naidoo. (2023) Pharmacogenetics of anxiety and depression in Alzheimer's disease. Pharmacogenomics 24:1, pages 27-57.
Crossref
Crossref
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J. Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak & Lhassane Ismaili. (2022) Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules 28:1, pages 71.
Crossref
Crossref
Di Zhang, Nadya Mara Adelina, Ziluan Fan & Jiaren Liu. (2022) Phytochemical profile and biological activities from different parts of Vaccinium vitis-idaea. Journal of Berry Research 12:4, pages 445-462.
Crossref
Crossref
Nitin Kumar, Pankaj Gupta & Sahil Bansal. (2022) Progress and Development of Carbazole Scaffold Based as Potential Anti-
Alzheimer Agents Using MTDL Approach. Letters in Drug Design & Discovery 19:12, pages 1049-1067.
Crossref
Crossref
Marcella Catania, Laura Colombo, Stefano Sorrentino, Alfredo Cagnotto, Jacopo Lucchetti, Maria Chiara Barbagallo, Ilaria Vannetiello, Elena Rita Vecchi, Monica Favagrossa, Massimo Costanza, Giorgio Giaccone, Mario Salmona, Fabrizio Tagliavini & Giuseppe Di Fede. (2022) A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer’s disease. Molecular Psychiatry 27:12, pages 5227-5234.
Crossref
Crossref
Rima Hajjo, Dima A. Sabbah, Osama H. Abusara & Abdel Qader Al Bawab. (2022) A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. Diagnostics 12:12, pages 2975.
Crossref
Crossref
Olaia Martínez-Iglesias, Vinogran Naidoo, Iván Carrera, Lola Corzo & Ramón Cacabelos. (2022) Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer’s Disease. Pharmaceutics 14:11, pages 2447.
Crossref
Crossref
Tais de Cassia Ribeiro, Rafael Miguel Sábio, Marcela Tavares Luiz, Lucas Canto de Souza, Bruno Fonseca-Santos, Luis Carlos Cides da Silva, Márcia Carvalho de Abreu Fantini, Cleopatra da Silva Planeta & Marlus Chorilli. (2022) Curcumin-Loaded Mesoporous Silica Nanoparticles Dispersed in Thermo-Responsive Hydrogel as Potential Alzheimer Disease Therapy. Pharmaceutics 14:9, pages 1976.
Crossref
Crossref
Taís C. Ribeiro, Rafael M. Sábio, Gabriela C. Carvalho, Bruno Fonseca-Santos & Marlus Chorilli. (2022) Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment. International Journal of Pharmaceutics 624, pages 121978.
Crossref
Crossref
G. Dhamodharan & C. Gopi Mohan. (2021) Machine learning models for predicting the activity of AChE and BACE1 dual inhibitors for the treatment of Alzheimer’s disease. Molecular Diversity 26:3, pages 1501-1517.
Crossref
Crossref
Ramón Cacabelos. (2022) Pharmacogenetics for Improving Efficacy and Safety in Drug Development
and for Reducing Costs in Alzheimer’s Disease. Current Pharmacogenomics and Personalized Medicine 19:1, pages 3-6.
Crossref
Crossref
Ramon Cacabelos. 2022. Alzheimer's Disease Drug Development. Alzheimer's Disease Drug Development
404
417
.
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego & Juan C. Carril. (2022) Personalized Management and Treatment of Alzheimer’s Disease. Life 12:3, pages 460.
Crossref
Crossref
Xianhai Huang & Robert Aslanian. 2022. Contemporary Accounts in Drug Discovery and Development. Contemporary Accounts in Drug Discovery and Development
51
83
.
Olaia Martínez-Iglesias, Vinogran Naidoo, Iván Carrera & Ramón Cacabelos. (2022) Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer’s Disease. International Journal of Molecular Sciences 23:5, pages 2446.
Crossref
Crossref
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego & Juan C. Carril. 2022. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
275
387
.
Salwa & Lalit Kumar. (2021) Engrafted stem cell therapy for Alzheimer's disease: A promising treatment strategy with clinical outcome. Journal of Controlled Release 338, pages 837-857.
Crossref
Crossref
Matteo Borgini, Pravat Mondal, Ruiting Liu & Peter Wipf. (2021) Chemical modulation of Kv7 potassium channels. RSC Medicinal Chemistry 12:4, pages 483-537.
Crossref
Crossref
Lhassane Ismaili, Julie Monnin, Adeline Etievant, Raquel L. Arribas, Lucía Viejo, Bernard Refouvelet, Ondrej Soukup, Jana Janockova, Vendula Hepnarova, Jan Korabecny, Tomas Kucera, Daniel Jun, Rudolf Andrys, Kamil Musilek, Aurelie Baguet, Eva M. García-Frutos, Angela De Simone, Vincenza Andrisano, Manuela Bartolini, Cristóbal de los Ríos, José Marco-Contelles & Emmanuel Haffen. (2021)
(±)-
BIGI-3h
: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer’s Disease
. ACS Chemical Neuroscience 12:8, pages 1328-1342.
Crossref
Crossref
Baiwen Zhang, Lan Lin & Shuicai Wu. (2021) A Review of Brain Atrophy Subtypes Definition and Analysis for Alzheimer’s Disease Heterogeneity Studies. Journal of Alzheimer's Disease 80:4, pages 1339-1352.
Crossref
Crossref
Ramón Cacabelos, Juan Carril, Lola Corzo, Lucía Fernández-Novoa, Rocío Pego, Natalia Cacabelos, Pablo Cacabelos, Margarita Alcaraz, Iván Tellado & Vinogran Naidoo. (2021) Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease. Pharmaceuticals 14:4, pages 366.
Crossref
Crossref
Sarah Lye, Caitlin E. Aust, Lyn R. Griffiths & Francesca Fernandez. (2021) Exploring new avenues for modifying course of progression of Alzheimer's disease: The rise of natural medicine. Journal of the Neurological Sciences 422, pages 117332.
Crossref
Crossref
Sai-Sai Xie, Jing Liu, Chunli Tang, Chengyun Pang, Qing Li, Yuelian Qin, Xiaojie Nong, Zhipeng Zhang, Jie Guo, Maojun Cheng, Weizhong Tang, Ningsheng Liang & Neng Jiang. (2020) Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer’s disease. European Journal of Medicinal Chemistry 202, pages 112475.
Crossref
Crossref
John R. Horsley, Blagojce Jovcevski, Kate L. Wegener, Jingxian Yu, Tara L. Pukala & Andrew D. Abell. (2020) Rationally designed peptide-based inhibitor of Aβ42 fibril formation and toxicity: a potential therapeutic strategy for Alzheimer's disease. Biochemical Journal 477:11, pages 2039-2054.
Crossref
Crossref
Ramon Cacabelos. (2020) Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia. International Journal of Molecular Sciences 21:9, pages 3059.
Crossref
Crossref
Luke Cassidy, Francesca Fernandez, Joel B. Johnson, Mani Naiker, Akeem G. Owoola & Daniel A. Broszczak. (2020) Oxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics. Complementary Therapies in Medicine 49, pages 102294.
Crossref
Crossref
Luca Piemontese, Roberta Sergio, Federica Rinaldo, Leonardo Brunetti, Filippo M. Perna, M. Amélia Santos & Vito Capriati. (2020) Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2-Hydroxyphenylbenzimidazole-Based Scaffolds en Route to Donepezil-Like Compounds. Molecules 25:3, pages 574.
Crossref
Crossref
Chandra Bhushan Mishra, Siddharth Gusain, Shruti Shalini, Shikha Kumari, Amresh Prakash, Namrata Kumari, Anita Kumari Yadav, Jyoti Kumari, Kundan Kumar & Manisha Tiwari. (2020) Development of novel carbazole derivatives with effective multifunctional action against Alzheimer’s diseases: Design, synthesis, in silico, in vitro and in vivo investigation. Bioorganic Chemistry 95, pages 103524.
Crossref
Crossref
Ting Zhang, Wei Ke, Xuan Zhou, Yun Qian, Su Feng, Ran Wang, Guizhong Cui, Ran Tao, Wenke Guo, Yanhong Duan, Xiaobing Zhang, Xiaohua Cao, Yousheng Shu, Chunmei Yue & Naihe Jing. (2019) Human Neural Stem Cells Reinforce Hippocampal Synaptic Network and Rescue Cognitive Deficits in a Mouse Model of Alzheimer's Disease. Stem Cell Reports 13:6, pages 1022-1037.
Crossref
Crossref
Marcella Catania, Giorgio Giaccone, Mario Salmona, Fabrizio Tagliavini & Giuseppe Di Fede. (2019) Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder. Frontiers in Aging Neuroscience 11.
Crossref
Crossref
Ramón Cacabelos, Juan C. Carril, Ana Sanmartín & Pablo Cacabelos. 2019. Pharmacoepigenetics. Pharmacoepigenetics
191
424
.
Anchalee Prasansuklab, Atsadang Theerasri, Matthew Payne, Alison T. Ung & Tewin Tencomnao. (2018) Acid-base fractions separated from Streblus asper leaf ethanolic extract exhibited antibacterial, antioxidant, anti-acetylcholinesterase, and neuroprotective activities. BMC Complementary and Alternative Medicine 18:1.
Crossref
Crossref
Qi He, Jing Liu, Jin-Shuai Lan, Jiaoli Ding, Yongbing Sun, Yuanying Fang, Neng Jiang, Zunhua Yang, Liyuan Sun, Yi Jin & Sai-Sai Xie. (2018) Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer’s disease: Design, synthesis and biological evaluation. Bioorganic Chemistry 81, pages 512-528.
Crossref
Crossref
Ziqian Cheng, Xiaohan Zou, Yang Jin, Shuohui Gao, Jiayin Lv, Bingjin Li & Ranji Cui. (2018) The Role of KLF4 in Alzheimer’s Disease. Frontiers in Cellular Neuroscience 12.
Crossref
Crossref
Luca Piemontese, Gabriele Vitucci, Marco Catto, Antonio Laghezza, Filippo Perna, Mariagrazia Rullo, Fulvio Loiodice, Vito Capriati & Michele Solfrizzo. (2018) Natural Scaffolds with Multi-Target Activity for the Potential Treatment of Alzheimer’s Disease. Molecules 23:9, pages 2182.
Crossref
Crossref
Vladimir Kulchitsky, Alexandra Zamaro, Valeria Navitskaya, Yuri Shanko, Svetlana Pashkevich, Yulya Stukach & Stanislav Koulchitsky. (2018) Perspectives of stem cells use in alzheimer’s disease treatment. Journal of Neurology & Stroke 8:3.
Crossref
Crossref